Non-Hodgkin's Lymphoma | Page 6 | NCCN Continuing Education

Updates in the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Sequencing Therapy and the Role of MRD Testing

There is a continuing need to educate hematologists and oncologists about the challenges and special considerations involved in the management of patients with CLL/SLL so that they can make informed clinical decisions and develop an individualized treatment plan for their patients.

NCCN Pharmacy Updates: Treatment Advances for Pediatric B-Cell Non-Hodgkin's Lymphomas

This is a potentially curable malignancy and systemic therapy is the mainstay of treatment. Understanding the diagnosis, workup, and subsequent treatment for early stage and later stage disease will improve understanding and subsequently, education for patients and caregivers alike.

Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: Updates in the Treatment of Follicular Lymphoma and Diffuse Large B-Cell Lymphomas

Case managers and medical directors are challenged to maintain a high awareness of the recent therapeutic advances in the management of FL and DLBCL in order to develop an efficient coordinated treatment approach that incorporates novel therapies in the appropriate patient population.

NCCN Oncology Case Manager and Medical Director Program: Updates in the Treatment of Follicular Lymphoma and Diffuse Large B-Cell Lymphomas

Case managers and medical directors are challenged to maintain a high awareness of the recent therapeutic advances in the management of FL and DLBCL in order to develop an efficient coordinated treatment approach that incorporates novel therapies in the appropriate patient population.

Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - B-Cell Lymphomas

During this tumor board, the faculty will discuss recent advances in the diagnosis and treatment of diffuse large B-cell lymphomas (DLBCL).

NCCN Guidelines® Insights - B-Cell Lymphomas, Version 3.2019

These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - B-Cell Lymphomas

Diagnosis and Treatment of Diffuse Large B-Cell Lymphomas (DLBCL)

Keynote Session: Patient Experience with Innovative Therapies

The development of new and innovative cancer treatments has expanded the options available to manage patients with cancer. However, with these advances come challenges for healthcare providers and patients.

Case 3: Immunomodulatory Drugs (IMiDs) for Relapsed/Refractory Follicular Lymphoma

You recently participated in education on Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas. Here is your chance to earn additional CME/CE and test your knowledge. Try your skills at this challenging case.

Case 3: Immunomodulatory Drugs (IMiDs) for Relapsed/Refractory Follicular Lymphoma

You recently participated in education on Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas. Here is your chance to earn additional CME/CE and test your knowledge. Try your skills at this challenging case.

Pages